Cunesoft
Key Facts
| Invested since | 2014 |
| Based in | Bavaria |
About the company
Headquartered in Munich, Germany, Cunesoft’s online software solutions have been built to provide industry-breaking value for life sciences organizations. The software suite is available in individual but integrated modules. Customers select their relevant modules for their needs.
A smart integration of best practice processes such as the preparation of drug submissions combined with an automatic electronic submission publishing function, reduces the process time by 90%. Other software modules support critical quality assurance process and ensure quality compliance while delivering significant process reduction time. The system has been architected to support collaboration across company boundaries and via that help life sciences organizations to become faster and more effective.
The SaaS (Software as a Service) concept allows all customers to benefit of an immediate system availability. Implementation times are reduced from months to hours. System maintenance is provided centrally by Cunesoft and reduces costs on customer’s side. Typical project ROI’s are below 6 months.
Cunesoft’s positioning is very attractive for companies of all sizes. Small organizations find very attractive entry level price models while large organizations benefit by its scalability. Currently drug manufacturers from emerging regulated markets, biotechnology companies, generics organizations and originator drug producers are happy and referenceable customers of the Cunesoft online software platform.
Do you want to
know more about this company?
Cunesoft in the news
Zum Artikel
Cunesoft receives a seven-digit Series-A financing from Occident Group, High-Tech-Gruenderfonds and Bayern Kapital
More startups from Life Sciences
mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …
Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
